|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
TNF-α is a key cytokine for both hepatitis C progression and psoriasis.
|
30398009 |
2018 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The relationship between serum anti-TNF, ADA levels and clinical efficacy in long-term treated patients with psoriasis has not yet been determined, so the potential role of these parameters in guiding dose escalation in this scenario is unknown.
|
27943384 |
2017 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting the TNFα pathway is a validated approach to the treatment of psoriasis.
|
28818461 |
2018 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Blocking of CXCL16 expression by effective treatment of psoriasis patients with tumor necrosis factor-α blockers further supported the pathogenic role of this chemokine.
|
28942364 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis.
|
17074928 |
2006 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Psoriasis (Ps) is an autoimmune disease characterized by keratinocyte hyperproliferation and chronic inflammation, with increased expression of tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF).
|
24587411 |
2014 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Etanercept is a TNFα receptor Fc fusion protein used for the treatment of rheumatic disease and psoriasis.
|
28638112 |
2017 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective.
|
15251081 |
2004 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The study included 56 patients (42 male and 14 female) affected by moderate-to-severe psoriasis (mean PASI: 12.8 ± 6.9 SD) treated with anti-TNF-α and/or anti IL 12, 23 and/or anti-CD11 drugs with a diagnosis of LTBI.
|
28547750 |
2017 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Tumor necrosis factor α (TNFα) is a proinflammatory cytokine, and elevated levels of TNFα in serum are associated with various autoimmune diseases, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn's disease (CD), psoriasis, and systemic lupus erythaematosus.
|
29575262 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
T helper (Th) cytokines in psoriasis upregulate keratin (K)17, which modulates TNF-α transduction, leading to vascular adhesion molecule upregulation and lymphocytic extravasation.
|
28940220 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To determine the incidence of LTBI and active tuberculosis in patients with psoriasis receiving TNF inhibitor therapy.
|
29455561 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This retrospective study aimed to evaluate the long-term efficacy and effects on lipid profile and Atherogenic Index of antitumor necrosis factor (TNF)α therapy with adalimumab in patients with moderate-to-severe psoriasis or psoriatic arthritis.
|
29564871 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
To evaluate the risk of AF and major adverse cardiovascular events (MACE) associated with use of ustekinumab vs tumor necrosis factor inhibitors (TNFi) in patients with psoriasis or psoriatic arthritis.
|
30916734 |
2019 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found that the TNF-alpha-308A allele frequency was significantly decreased among patients with early-onset psoriasis in comparison with control subjects (7.5% vs. 15.4%, P = 0.022), whereas in the same patients the frequency of the TNF-alpha-238A allele was significantly increased as compared with the controls (16.8% vs. 3.1%, P = 0.000017, odds ratio 8.79, 95% confidence interval 2.606-29.678).
|
17553030 |
2007 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
There are over 300,000 patients worldwide being treated with agents that specifically block the biological activities of interleukin-1 (IL-1) or tumor necrosis factor (TNF) for reducing the severity of autoimmune diseases such as rheumatoid arthritis, Crohn's disease or psoriasis.
|
12763679 |
2003 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The <i>in vitro</i> identified EV-associated microRNA signature was increased in serum of autoimmune patients with psoriasis and returned to healthy levels upon effective treatment with etanercept, a biological drug targeting the TNF pathway and suppressing inflammation.
|
28077577 |
2017 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Topical application of psoralen liposomal gels on imiquimod induced psoriatic plaque model reduced the symptoms of psoriasis and levels of key psoriatic cytokines such as tumor necrosis factor-α, IL-17 and IL-22.
|
27777066 |
2017 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The use of tumor necrosis factor alpha (TNF-α) antagonists has greatly improved clinical management of psoriasis and other inflammatory diseases, but acute and chronic adverse reactions, including demyelination, are becoming increasingly recognized.
|
25692775 |
2018 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Tumor necrosis factor alpha (TNF-α) expression amplifies to excess amounts in several disorders such as rheumatoid arthritis and psoriasis.
|
29881431 |
2018 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The use of TNF inhibitors in psoriasis showed a significant reduction in the risk of MI compared with topical agents and a non-significant reduction compared with MTX.
|
27881030 |
2018 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This suggests that TNFA gene promoter polymorphism in the region examined is less associated with the pathogenesis of psoriasis in Japanese patients, however there might be the possibility that TNFA gene promoter polymorphism is associated with GPP.
|
12234707 |
2002 |
|
Psoriasis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
As compared to normal skin (n = 7), there was an increased expression of TNF-alpha, IL-12p40, and IL-8, a decreased expression of TGF-beta1, and a lack of IL-10, similar to the findings in active psoriasis (n = 8).
|
15186319 |
2004 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results of this study are an important step in the characterization of the pharmacogenetic profile associated with anti-TNF response in psoriasis.
|
25403996 |
2015 |
|
Psoriasis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Psoriasis can also be associated with other comorbidities such as joint disease, cardiovascular disease, and depression, which can add to the complexity of treatment.</p> <p>Adalimumab is a recombinant, fully human, monoclonal antibody against tumor necrosis factor alpha (TNF-α), which blocks the interaction of TNF with both of its cell-surface receptors, with high affinity and specificity.
|
28809993 |
2017 |